Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

Oncology

Volumn 65, Issue 4, 2003, Pages 316-322

  Fanfani, Francesco ^a   Ferrandina, Gabriella ^a   Corrado, Giacomo ^a   Fagotti, Anna ^a   Zakut, Haim Vito ^a   Mancuso, Salvatore ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Advanced stage; Interval debulking surgery; Neoadjuvant chemotherapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYTOREDUCTION; FEMALE; HUMAN; INTERVAL DEBULKING SURGERY; OUTCOMES RESEARCH; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; LIFE TABLES; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; OVARIECTOMY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0347319568     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074644     Document Type: Article

References (30)

1. Ozols RF: Management of advanced ovarian cancer consensus summary. Semin Oncol 2000;27:47-49.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinumera: A meta-analysis. J Clin Oncol 2002;20:1248-1259.
3. Schwartz PE, Rutherford TJ, Chambers JT, Kohoron EI, Thiel RP: Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 1999;72:93-99.
4. Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 1998;69:103-108.
5. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, Montz FJ: A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:1532-1540.
6. van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S: The effect of debulking surgery after induction chemotherapy on the prognosis in advancer epithelial ovarian cancer. N Engl J Med 1995;332:629-634.
7. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, Moore DH: A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: A Gynecologic Oncology Group study. ASCO Proc (abstract No 802), 2002.
8. Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M, Van Dam P: Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000;27(3 Suppl 7):31-36.
9. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplet J, Mathevet P, Lhomme C, Scherer C, Tigaud JD, Benchaib M, Fourme E, Castaigne D, Querleu D, Dargent D: Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 2001;91:2329-2334.
10. Kayikciog Lu F, Kose MF, Boran N, Caliskan E, Tulunay G: Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:466-470.
11. Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G, Rea S: Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaecol Oncol 2001;22:287-291
12. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM: Primary surgical therapy of ovarian cancer: How much and when. Gynecol Oncol 1991;42:195-200.
13. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton J: Neoadjuvant chemotherapy and interval debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-150.
14. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL: Randomized trial comparing two combination chemotherapy regimens (CHAP vs CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5:1157-1168.
15. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL: Long-term survival in ovarian cancer: Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991;27:1367-1372.
16. Chambers JT, Chambers SK, Voynick IM, Schwartz PE: Neoadjuvant chemotherapy in stage x ovarian carcinoma. Gynecol Oncol 1990;37:327-331.
17. Surwit E, Childers J, Atlas I, Nour M, Hallum A, Alberts D: Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996;6:356-361.
18. Nelson BE, Rosenfield AT, Schwartz PE: Pre-operative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11:166-172.
19. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC: Ovarian carcinoma: Value of CT in predicting success of debulking surgery. AJR Am J Roentgenol 1995;165:875-878.
20. International Union Against Cancer, TNM Atlas, ed 4. Paris, Springer, 1998.
21. Eisenkop SM, Spirtos NM: What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2002;82:489-497.
22. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-253.
23. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996;50:163-170.
24. van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HWA, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R: Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000;79:444-450.
25. Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE: Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med 1996; 41:140-142.
26. Chi DS, Venkatraman ES, Masson V, Hoskins WJ: The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2001;77:227-231.
27. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD: Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity. Obstet Gynecol 1986;67:783-787.
28. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florak G, von Hundelshausen B, Pachyn D, Ulm K, Graeft H: Neodjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in international federation of gynecology and obstetrics stage IIIc ovarian carcinoma. Cancer 2001;92:2585-2591.
29. Hoskins WJ, McGuire WP, Brady MF, Humesley HM, Creasman WT, Berman M, Ball M, Berek JS: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian cancer. Am J Obstet Gynecol 1994;4:974-980.
30. Chan YM, Ngan HYS, Wong LC: Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study. Gynecol Oncol 2003;88:9-16.